Key facts
- Ocuwell’s last known valuation is $3.6M (Oct 2025).
- It has raised $500K; the latest was Seed Round ($500K) in Oct 2025.
- Notable investors include Northern Gritstone, Deepbridge Capital, LYVA Labs, Sci-Tech Daresbury, The University of Liverpool.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Ocuwell
- ·The full record, as it builds
Funding rounds
No funding rounds for Ocuwell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ocuwell
Developer of ophthalmic diagnostic technology intended to improve access to advanced eye care. The company offers a platform featuring precision corneal topography, digital imaging, and data-driven analysis for eye health assessment, enabling ophthalmologists, optometrists, and vision care providers to deliver accurate diagnostics and early detection of corneal conditions to patients seeking accessible and reliable vision care.
- Sector
- Healthcare
- HQ
- Liverpool, United Kingdom
- Founded
- 2020
- Employees
- 10
- Website
- ocuwell.com/
- Ownership
- Privately Held (backing)
Ocuwell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ocuwell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ocuwell in its N-PORT filings yet. We sweep new filings monthly.